Quanterix (NASDAQ:QTRX) is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.
The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers. In addition, Quanterix offers the SP-X Imaging and Analysis System for multiplexed protein detection, along with a range of reagent kits, calibrators and consumables. These products address applications in neurodegenerative disease, oncology, immunology, infectious disease and cardiovascular research, supporting both preclinical studies and clinical trial workflows.
Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix went public on the Nasdaq under the ticker QTRX in 2017. The company serves a global customer base that includes academic institutions, biopharmaceutical companies and contract research organizations. Quanterix maintains commercial and support offices in North America, Europe and the Asia-Pacific region to facilitate instrument deployment, training and technical service.
Leadership is led by President and Chief Executive Officer Kevin Hrusovsky, under whose direction Quanterix has expanded its technology applications and strategic collaborations. The company continues to invest in research and development to enhance assay menus, improve automation and extend digital immunoassay capabilities into new areas of translational research and clinical diagnostics.
